Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
Chronic Lymphocytic Leukemia (CLL)|Lymphoma, Non-Hodgkin (NHL)|Acute Myeloid Leukemia (AML)|Multiple Myeloma (MM)
DRUG: CAL-101
To evaluate the safety of CAL-101 and determine the dose limiting toxicity in patients with hematologic malignancies., 28 days
To evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following CAL-101 treatment in patients with hematologic malignancies., 28 Days
A Phase 1, sequential dose escalation followed by cohort expansion study of CAL-101, an oral inhibitor of PI3K delta, in patients with relapsed or refractory CLL, select B-cell NHL and AML.